Applying new data to manage CINV: achieving optimal outcomes through a comprehensive care model.
Padezanin
Sharon
S
Oncology Nursing Society, Pittsburgh, PA, USA.
D000932:Antiemetics / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000077608:Aprepitant; D003191:Comprehensive Health Care / Q000458:organization & administration; D019317:Evidence-Based Medicine; D006801:Humans; D007546:Isoquinolines / Q000627:therapeutic use; D017146:Models, Organizational; D009025:Morpholines / Q000627:therapeutic use; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control*; D009369:Neoplasms / Q000628:therapy*; D024802:Nurse's Role; D009859:Oncology Nursing / Q000458:organization & administration; D000077924:Palonosetron; D010348:Patient Care Team / Q000458:organization & administration*; D017410:Practice Guidelines as Topic; D011812:Quinuclidines / Q000627:therapeutic use; D017749:Total Quality Management / Q000458:organization & administration; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
D000932:Antiemetics; D000970:Antineoplastic Agents; D007546:Isoquinolines; D009025:Morpholines; D011812:Quinuclidines; D000077608:Aprepitant; D000077924:Palonosetron